<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373370</url>
  </required_header>
  <id_info>
    <org_study_id>NI 16007</org_study_id>
    <nct_id>NCT03373370</nct_id>
  </id_info>
  <brief_title>Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology</brief_title>
  <acronym>ADDITION</acronym>
  <official_title>Project to Accelerate the Diagnosis of TTR Amyloidosis by Use of Molecular Biology in First Intention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral neuropathies are diseases that affect the nervous system outside the brain and
      spinal cord, their prevalence is 1% in the general population, the causes are extremely
      varied with more than 200 identified causes; the main ones are diabetes, excessive alcohol
      consumption and chemotherapy. They may be sometimes disabling but generally preserve
      autonomy.

      Transthyretin amyloidosis is a rare multisystematic hereditary disease with autosomal
      dominant transmission. They present usually as a peripheral neuropathies (FAP). They are due
      to a point mutation of the transthyretin gene (chr 18q). FAP is secondary to endoneurial
      amyloid deposits and are characterized by a slowly progressive sensory, motor and autonomic.
      FAP is the most severe hereditary polyneuropathy of the adult are irreversible and fatal
      within 5 to 12 years from onset.

      Most frequent mutation of TTR gene is located on the second exon; but more than 100 mutations
      have been reported.

      Prevalence of FAP is 1 per 1 million inhabitants. They have been reported until 1990s' in
      four endemic areas North of Portugal, Sweden, Japan and Majorca. In these areas, diagnosis is
      facilitated because of the stereotypical presentation : a length-dependent polyneuropathy
      with predominant involvement of thermal and pain sensations and autonomic dysfunction, early
      onset in the third decade and a predominant Met30 TTR mutation. Positive family history is
      frequent 85% (one of the parents is affected). Diagnosis requires detection of TTR mutation
      by molecular biology (blood sample) and characterization of amyloid deposit on labial
      salivary gland biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study of the TTR gene by complete sequencing; search for amyloidogenic mutations of the TTR
      gene (according to the site http: // amyloidosismutations.com / mut-attr.php) in the
      laboratory of molecular biology of the CHU BICÊTRE (APHP) managed by Pr Anne Mantel.

      Preselection of the cases to be tested among the cases of peripheral neuropathies of
      indetermined cause referred via the network Cornamyl of which the reference centers of the
      neuromuscular diseases are belonging .

      Currently, FAP is a worldwide disease. Diagnosis of TTR-FAP is extremely difficult and
      usually delayed by 4 years in non endemic areas for many reasons :

        -  positive family history are lacking in 50% of cases (sporadic forms).

        -  incomplete ability of biopsies to characterize amyloid deposits.

        -  clinical presentation is varied and may mimick many types of rare peripheral
           neuropathies: CIDP, axonal idiopathic polyneuropathy, upper limb neuropathies, recurrent
           carpal tunnel syndrome after surgery, ataxic neuropathy, motor neuropathy.

      Conversely to endemic areas, look for V30M mutation is not enough to exclude TTR-FAP, TTR
      gene sequencing is required.

      With the help of the french network for FAP (Cornamyl), cases have been identified in 81/100
      geographical departments, with a wide genetic heterogeneity (41 mutations reported) ; age of
      onset is late: 75% after 50 yo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Anticipated">March 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of amyloidogenic TTR mutation</measure>
    <time_frame>1 day</time_frame>
    <description>To identify the rate of amyloidogenic TTR mutation in progressive idiopathic polyneuropathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify the rate of amyloidogenic TTR mutation in different subgroups of patients with neuropathy</measure>
    <time_frame>1 day</time_frame>
    <description>To identify the rate of amyloidogenic TTR mutation in different subgroups of patients with neuropathy : disabling neuropathy (including ataxic).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the rate of amyloidogenic TTR mutation in different subgroups of patients with neuropathy :variant Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</measure>
    <time_frame>1 day</time_frame>
    <description>To identify the rate of amyloidogenic TTR mutation in different subgroups of patients with neuropathy :variant Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the rate of amyloidogenic TTR mutation in different subgroups of patients with neuropathy : upper limb onset neuropathy.</measure>
    <time_frame>1 day</time_frame>
    <description>To identify the rate of amyloidogenic TTR mutation in different subgroups of patients with neuropathy : upper limb onset neuropathy.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Polyneuropathy</condition>
  <condition>Diagnosis</condition>
  <condition>Idiopathic Progressive Neuropathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Multicentric prospective population in tertiary referal center for neuromuscular diseases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A. Adult (&gt;50 yo)

          -  Chronic Peripheral neuropathies (progressing since 12 months),

          -  Peripheral neuropathies documentated by ENMG.

               1. Chronic polyneuropathy with dysautonomia (orthostatic hypotension) without
                  diabetes

               2. Atypical CIDP (situations C, D (even with high protid content on CSF) &amp; E as
                  defined by the French group for study of CIDP).

               3. Disabling neuropathy (gait or balance disorder)

               4. Neuropathies with upper limb onset who underwent previously CTS surgery without
                  success.

               5. SLA-like syndrome : areflexia with sensory alterations on ENMG. 6: Deterioration
                  of SNAPs' amplitudes on NCS &gt; 30% in less than6 months by the same NCS laboratory
                  Mandatory : A+B+C one of 1 to 6

        Exclusion criteria :

          -  Amyloid deposit characterized on biopsy

          -  Causes of chronic polyneuropathy : Diabetes mellitus, Chronic alcoholic intoxication

          -  CIDP responding to IVIg or corticosteroids (improvement by 1 point of ONLS).

          -  Neuropathy associated with monoclonal gammapathy and i) anti-MAG activity or ii) POEMS
             syndrome or) CANOMAD syndrome.

          -  Ataxic Neuropathy due to vitamine B12 deficiency

          -  Ataxic Neuropathy due to IgM anti-MAG,

          -  CANOMAD syndrome,

          -  Ganglionopathy by Sjögren's syndrome, or paraneoplastic syndrome with Anti- Hu
             Antibodies, chemotherapy induced (cis-platine, oxaliplatine).

          -  Positive family history of FAP or FAC

          -  Proven AL amyloidosis

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David ADAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bicetre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David ADAMS</last_name>
    <phone>01 45 21 27 11</phone>
    <email>david.adams@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline LABEYRIE</last_name>
    <phone>0145213159</phone>
    <email>celine.labeyrie@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <state>Kremlin Bicetre</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David ADAMS</last_name>
      <phone>01 45 21 27 11</phone>
      <email>david.adams@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Céline LABEYRIE</last_name>
      <phone>0145213159</phone>
      <email>celine.labeyrie@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Martinique</name>
      <address>
        <city>Martigues</city>
        <state>Martinique</state>
        <zip>97200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aissatou Signate</last_name>
      <phone>05 96 60 65 74</phone>
      <email>aissatou.Signate@chu-fortdefrance.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <state>Saint Etienne</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANTOINE Jean-Christophe</last_name>
      <phone>00(33) 4 77 12 78 05</phone>
      <email>j.christophe.antoine@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmeline Lagrange</last_name>
      <phone>04 76 76 61 61</phone>
      <email>elagrange@grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline TARD</last_name>
      <phone>00 (33) 320445962</phone>
      <email>celine.tard@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MAGY</last_name>
      <phone>05 55 05 65 61</phone>
      <email>laurent.magy@unilim.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahram ATTARIAN</last_name>
      <phone>04 91 38 65 79</phone>
      <email>sattarian@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital guy-de-Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAUL JUNTAS MORALES</last_name>
      <phone>04 67 33 78 22</phone>
      <email>r-juntasmorales@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VIALA Karine</last_name>
      <phone>0142161945</phone>
      <email>karine.viala@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANDONI ECHANIZ-LAGUNA</last_name>
      <phone>03 88 12 85 59</phone>
      <email>andoni.echaniz-laguna@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

